Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Purchase on Springer Link

Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Legrand O, Perrot JY, Baudard M, Cordier A, Lautier R, Simonin G et al. The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood 2000; 96: 870–877.

    CAS  PubMed  Google Scholar 

  2. Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001; 7: 1490–1496.

    CAS  PubMed  Google Scholar 

  3. Alan KB, William JK, Anthony HG, Donald M, Ann H, Archie GP et al. The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary analysis of 1115 patients in the MRC AML15 trial. Blood 2006; 108 (11; ASH2006 abstracts): 13.

    Google Scholar 

  4. Ikemoto N, Kumar RA, Ling TT, Ellestad GA, Danishefsky SJ, Patel DJ . Calicheamicin–DNA complexes: warhead alignment and saccharide recognition of the minor groove. Proc Natl Acad Sci USA 1995; 92: 10506–10510.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Walter RB, Gooley TA, van dV V, Loken MR, van Dongen JJ, Flowers DA et al. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood 2007; 109: 4168–4170.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Sievers EL . Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse. Expert Opin Biol Ther 2001; 1: 893–901.

    Article  CAS  PubMed  Google Scholar 

  7. Buckwalter M, Dowell JA, Korth-Bradley J, Gorovits B, Mayer PR . Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Pharmacol 2004; 44: 873–880.

    Article  CAS  PubMed  Google Scholar 

  8. Dowell JA, Korth-Bradley J, Liu H, King SP, Berger MS . Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol 2001; 41: 1206–1214.

    Article  CAS  PubMed  Google Scholar 

  9. Jeffrey R, Bassem R, Paul B, Gary D, Norman L, Jeffrey T et al. Improved remission induction rate of childhood AML: preliminary results of the AML02 trial. Blood 2005; 106 (11; ASH 2005 abstract): 275.

    Google Scholar 

  10. Coustan-Smith E, Ribeiro RC, Rubnitz JE, Razzouk BI, Pui CH, Pounds S et al. Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. Br J Haematol 2003; 123: 243–252.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We are grateful to Dr Kristine Crews for providing her input in preparing this report, to Dr Erin Schuetz for providing supporting lab materials and to Dr Donald Samulack for scientific editing. This work was supported in part by the National Institutes of Health, National Institute of General Medical Sciences Pharmacogenetics Research Network and Database (U01GM61374; http://www.pharmgkb.org) under Grant U01 GM61393; by the Cancer Center Support Grant CA-21765; and by the American Lebanese Syrian Associated Charities (ALSAC).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J K Lamba.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lamba, J., Pounds, S., Cao, X. et al. Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study. Leukemia 23, 402–404 (2009). https://doi.org/10.1038/leu.2008.185

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2008.185

This article is cited by

Search

Quick links